Ovarian Cancer Clinical Trials in Chicago, Illinois

19 studies are recruiting for ovarian cancer in Chicago, Illinois right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

    The purpose of this study is to evaluate INCB123667 versus investigator's choice of chemotherapy in participants with platinum-resistant ovarian cancer with cyclin E1 overexpression.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    The University of Chicago Medicine, Chicago, Illinois
    Locations
    192 in total
    Run by
    Incyte Corporation

    See if you can join NCT07214779 on ClinicalTrials.gov

  2. Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

    This study is researching an experimental drug called ubamatamab, also referred to as "study drug". The study is focused on participants who have advanced ovarian cancer. The aim of the study is to see how safe, tolerable, and effective the study drug is on its own and in combination with other ant…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    University of Chicago, Chicago, Illinois
    Locations
    56 in total
    Run by
    Regeneron Pharmaceuticals

    See if you can join NCT06787612 on ClinicalTrials.gov

  3. Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

    The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-M07D1 in patients with HER2 expressing advanced tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of Illinois Cancer Center, Chicago, Illinois
    Locations
    26 in total
    Run by
    SystImmune Inc.

    See if you can join NCT06293898 on ClinicalTrials.gov

  4. A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

    The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of Chicago Hospital, Chicago, Illinois
    Locations
    39 in total
    Run by
    Eli Lilly and Company

    See if you can join NCT06465069 on ClinicalTrials.gov

  5. Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors

    The primary purpose of this study is to determine whether the investigational drug XmAb541 is safe and well tolerated, and to determine an optimal and safe dose(s) for further study. The study will also evaluate the effect of XmAb541 on tumor outcomes.

    Stage
    Phase 1
    Ages
    15 and older
    Site
    University of Chicago Medical Center, Chicago, Illinois
    Locations
    22 in total
    Run by
    Xencor, Inc.

    See if you can join NCT06276491 on ClinicalTrials.gov

  6. A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab

    This study is researching an investigational drug called REGN5668 : * alone or, * combined with cemiplimab (also known as REGN2810) or, * combined with both cemiplimab and fianlimab (also known as REGN3767), or * combined with ubamatamab (also known as REGN4018), with or without sarilumab. The main…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois
    Locations
    28 in total
    Run by
    Regeneron Pharmaceuticals

    See if you can join NCT04590326 on ClinicalTrials.gov

  7. A Study of PHST001 in Advanced Solid Tumors

    This is a multi-center, first-in-human (FIH), open-label, Phase 1a/1b dose escalation and dose expansion study to assess the safety, PK, pharmacodynamics, and antitumor activity of PHST001 monotherapy (Phase 1a) or in combination with chemotherapy (Phase 1b) in adult participants with advanced rela…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of Chicago Medical Center, Chicago, Illinois
    Locations
    20 in total
    Run by
    Pheast Therapeutics

    See if you can join NCT06840886 on ClinicalTrials.gov

  8. A Trial to Evaluate Safety, Tolerability, and Preliminary Efficacy of Misetionamide (GP-2250) as Monotherapy or in Combination With Gemcitabine

    This is a phase 1 dose escalation trial of monotherapy misetionamide (also known as GP-2250) currently enrolling patients with platinum-resistant ovarian cancer (PROC) into Part 2 of the study. Part 1 of the study evaluating misetionamide in combination with gemcitabine in subjects with advanced pa…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Rush University Medical Center, Chicago, Illinois
    Locations
    4 in total
    Run by
    Persevere Therapeutics Inc.

    See if you can join NCT03854110 on ClinicalTrials.gov

  9. Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer

    This study is being done to answer the following question: What are the effects of a new drug or drugs on ovarian cancer? The pre-study screening may be done to test a sample of tissue for biomarkers to determine participation in the study.

    Stage
    Phase 2
    Ages
    18 and older
    Site
    The University of Chicago Medical Center, Chicago, Illinois
    Locations
    6 in total
    Run by
    Canadian Cancer Trials Group

    See if you can join NCT04918186 on ClinicalTrials.gov

  10. A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer

    Ovarian cancer (OC) is a lethal disease. The purpose of this study is to assess the safety, pharmacokinetics and efficacy of ABBV901, alone or in combination with bevacizumab, in participants with ovarian cancer. ABBV901 is an investigational drug for the treatment of ovarian cancer. This study has…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of Chicago Medical Center /ID# 278295, Chicago, Illinois
    Locations
    17 in total
    Run by
    AbbVie

    See if you can join NCT07278336 on ClinicalTrials.gov

  11. A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

    A Study of Emi-Le in Participants with Solid Tumors

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Northwestern University, Chicago, Illinois
    Locations
    26 in total
    Run by
    Day One Biopharmaceuticals, Inc.

    See if you can join NCT05377996 on ClinicalTrials.gov

  12. Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer

    The overarching objective of this project is to develop a pan-gynecologic cancer detection test using gynecologic (unique endometrial, cervical, and ovarian cancer) cancer-specific methylated DNA markers and high-risk human papilloma virus (HR-HPV) detected in vaginal fluid and/or plasma. This prop…

    Stage
    Not phased
    Ages
    18 and older
    Site
    University of Chicago, Chicago, Illinois
    Locations
    24 in total
    Run by
    Mayo Clinic

    See if you can join NCT05051722 on ClinicalTrials.gov

  13. TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention

    The aim of the project is to evaluate the risk-reducing salpingectomy with delayed oophorectomy as an alternative for risk-reducing salpingo-oophorectomy in high risk women with respect to ovarian cancer incidence.

    Stage
    Not phased
    Ages
    25 to 50
    Site
    UChicago Medicine, Chicago, Illinois
    Locations
    66 in total
    Run by
    University Medical Center Nijmegen

    See if you can join NCT04294927 on ClinicalTrials.gov

  14. A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer

    The goal of this clinical trial is to learn if the experimental antibody COM701 delays the progression of ovarian cancer in participants with Relapsed Platinum Sensitive Ovarian Cancer. It will also learn about the safety of COM701. The main questions the trial aims to answer are: * Does COM701, wh…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    The University of Chicago Medical Center, Chicago, Illinois
    Locations
    28 in total
    Run by
    Compugen Ltd

    See if you can join NCT06888921 on ClinicalTrials.gov

  15. A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

    This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel reversible small molecule inhibitor of PARG.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of Chicago Medical Center, Chicago, Illinois
    Locations
    14 in total
    Run by
    858 Therapeutics, Inc.

    See if you can join NCT06395519 on ClinicalTrials.gov

  16. A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

    Phase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    The University of Chicago Comprehensive Cancer Center, Chicago, Illinois
    Locations
    21 in total
    Run by
    Clasp Therapeutics, Inc.

    See if you can join NCT06778863 on ClinicalTrials.gov

  17. Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

    The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Northwestern University Feinberg School of Medicine, Chicago, Illinois
    Locations
    39 in total
    Run by
    SystImmune Inc.

    See if you can join NCT05983432 on ClinicalTrials.gov

  18. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

    International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical…

    Stage
    Not phased
    Ages
    Any age
    Site
    Massive Bio SYNERGY-AI site, Chicago, Illinois
    Locations
    68 in total
    Run by
    Massive Bio, Inc.

    See if you can join NCT03452774 on ClinicalTrials.gov

  19. Specimen and Data Study for Ovarian Cancer Early Detection and Prevention

    RATIONALE: To improve strategies for detection and prevention of early-stage disease. PURPOSE: This research study is collecting specimens and data to develop better methods for early detection and prevention of ovarian cancer among the high risk population and those who have the disease.

    Stage
    Not phased
    Ages
    18 to 80
    Site
    Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois
    Run by
    Northwestern University

    See if you can join NCT00005095 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.